Pfizer begins testing use of pneumococcal vaccine along with COVID-19 booster shot

The aim of the study is to understand if the combination of the vaccines is safe, and the immune response after adding the ...

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE ® ...

Pfizer Advances New Pediatric Pneumococcal “Catch-Up” Vaccine in Phase 3 Trial

Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Pfizer Inc. (PFE) is running a Phase 3 trial titled “A Phase 3, Randomized Double-Blind Trial to ...
MedPage Today

Pediatric Invasive Pneumococcal Disease: Shutting it Down in New Zealand, Again

"Young children have the greatest burden of severe disease, so choosing the right vaccine to protect against the main serotypes circulating in the community is crucial." — Tony Walls, MD, Department ...
Healio

Study provides more positive data on adult pneumococcal vaccine

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...

GSK’s New Pneumococcal Shot Reaches Key Milestone in Midlife Adult Trial

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter GlaxoSmithKline (GSK) has completed a Phase 1 trial titled “A Phase 1, Observer-Blind, ...
European Medical Journal

Vaccination Rates Lag in Patients With Rheumatic Diseases

Influenza and pneumococcal vaccination rates remain low in patients with rheumatic diseases. Find out more on AMJ.